newsfilter
← Latest News
ACCESS Newswire·

Kadmon to Present Initial Safety Data from Phase 1 Study of KD033 at the 2021 American Society of Clinical Oncology Annual Meeting

- Results Demonstrate KD033 was Well Tolerated in All Patients through Initial Dose Cohorts, Allowing for Continuation of Dose Escalation - NEW YORK, NY / ACCESSWIRE / May 19, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced initial safety dat